Top Journalists in Drugs and Pharmaceuticals
Matthew Herper STAT
Senior Writer for Medicine and Editorial Director of Events at STAT; long-time pharma/biotech columnist known for deep interviews and front-line coverage of medical innovation. Specialties: Drug R&D, biotech pipelines, FDA decisions, industry leaders, big-pharma strategy.
website | X (Twitter) | LinkedIn
Adam Feuerstein STAT
Senior Writer, Biotech at STAT; covers the crossroads of drug development, business and Wall Street, and co-hosts The Readout LOUD podcast. Specialties: Biotech, FDA advisory committees, earnings/Wall Street, clinical data readouts.
Helen Branswell STAT
STAT’s infectious diseases correspondent; an award-winning reporter on outbreaks and vaccine development with extensive FDA/industry interface coverage. Specialties: Vaccines, infectious diseases, pandemic preparedness, public health impacts for pharma.
Allison DeAngelis STAT
East Coast biotech and venture capital reporter at STAT; co-host of The Readout LOUD, focusing on where scientific ideas and money meet. Specialties: Biotech venture/capital, biopharma deals and M&A, startup pipelines, investor sentiment.
Robert Langreth Bloomberg News
Health reporter at Bloomberg who regularly breaks and explains major drug, FDA and market developments for global pharma. Specialties: Drug approvals/labels, obesity drugs, oncology, FDA safety, pharma business trends.
Riley Griffin Bloomberg News
Bloomberg health reporter focused on biosecurity and the government–industry nexus; previously covered U.S. pharma’s Covid response. Specialties: Biosecurity, pandemic preparedness, HHS/DoD medical countermeasures, Big Pharma.
Anna Edney Bloomberg News
National health care reporter at Bloomberg known for FDA and drug-quality investigations shaping industry practices. Specialties: FDA regulation, consumer health products, drug safety/quality, health policy.
Cynthia Koons Bloomberg News
U.S. Health Team Leader at Bloomberg; oversees and reports high-impact pharma coverage across pipelines, pricing and policy. Specialties: U.S. pharma leadership and strategy, market-moving drug news, corporate turnarounds.
Damian Garde Bloomberg News
Pharma reporter at Bloomberg (previously STAT’s national biotech reporter and Readout LOUD host), covering late-stage data, FDA moves and industry trends. Specialties: Biotech pipelines, oncology trials, dealmaking, investor dynamics.
Peter Loftus The Wall Street Journal
Wall Street Journal reporter covering drugs, devices and healthcare with frequent enterprise on blockbuster launches and FDA actions. Specialties: Pharmaceutical business/earnings, medical devices, vaccines, clinical/market impacts.
Jared S. Hopkins The Wall Street Journal
WSJ pharma reporter with regular exclusives on industry guidance, patent fights and regulatory shifts; maintains a direct tips channel. Specialties: Drug industry deals and litigation, biotech/pharma pipelines, global manufacturing shifts.
Joseph Walker The Wall Street Journal
WSJ reporter covering pharma/biotech; bylines span drug pricing, access and R&D developments. Specialties: Pharma and biotech business, patient access, pricing and payer dynamics.
Rebecca Robbins The New York Times
New York Times reporter focused on prescription drugs and pharma policy/business, with deep coverage of Medicare price talks and trade-related impacts. Specialties: Prescription drugs, Medicare negotiations, tariffs/supply chains, obesity drugs.
Email | X (Twitter) | Signal/WhatsApp
Christina Jewett The New York Times
NYT investigative reporter covering the FDA and medical products, often surfacing regulatory issues and safety signals that influence pharma. Specialties: FDA oversight, medical product safety, investigations affecting drug development.
Michael Erman Reuters
Reuters correspondent covering the U.S. pharma industry and regulatory developments with global reach. Specialties: Big Pharma pipelines and policy, Covid/post-Covid therapeutics, regulatory news.
Julie Steenhuysen Reuters
Reuters Health & Science correspondent with a long track record on vaccines, outbreaks and biopharma science. Specialties: Vaccines/infectious disease, FDA/CDC science, clinical breakthroughs affecting pharma.
Deena Beasley Reuters
Reuters correspondent based in Los Angeles reporting on pharma pricing, oncology advances and payer/regulatory impacts. Specialties: Pricing/cost-effectiveness, oncology and specialty drugs, payer and policy angles.
John Carroll Endpoints News
Editor & Founder of Endpoints News; widely followed voice on biopharma pipelines, dealmaking and policy with daily industry analysis. Specialties: Industry leadership, pipelines and financings, global biopharma trends, executive moves.
Email | X (Twitter) | Website
Zachary Brennan Endpoints News
Senior Editor at Endpoints covering the FDA and regulatory policy in depth, from guidance shifts to adcom debates. Specialties: FDA policy/regulation, Capitol Hill, approvals/advisory committees, global regulators.
Email | X (Twitter) | Website
Related Topics
Further Reading
Was this page helpful? We'd love your feedback — please email us at feedback@dealstream.com.